Szegedi István, Bomberák Dóra, Éles Zsolt, Lóczi Linda, Bagoly Zsuzsa
Department of Neurology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary
Lendület “Momentum” Hemostasis and Stroke Research Group of the Hungarian Academy of Sciences, Debrecen, Hungary
Pol Arch Intern Med. 2025 Aug 26;135(7-8). doi: 10.20452/pamw.17088. Epub 2025 Aug 11.
Cardiovascular and cerebrovascular diseases, encompassing conditions such as ischemic heart disease and ischemic stroke (IS), remain the leading global cause of death and disability. While traditional cardiovascular risk factors (eg, hypertension, diabetes, and atherosclerosis) are well established, emerging research underscores the critical role of gut microbiota in the development and progression of both cardiac and cerebrovascular events. The microbiota-gut-brain axis is a bidirectional communication system involving neural, immune, and metabolic pathways that link gut microbial activity to vascular and brain function. Dysbiosis, marked by reduced microbial diversity and an imbalance between beneficial and pathogenic taxa, has been associated with systemic inflammation, endothelial dysfunction, increased intestinal permeability, and thrombosis. Microbial metabolites, such as trimethylamine N‑oxide (TMAO), short‑chain fatty acids, and bile acid derivatives modulate blood-brain barrier integrity, vascular tone, and neuroinflammatory responses. Both cardiovascular and cerebrovascular diseases share key microbiota‑related mechanisms, including TMAO‑mediated platelet activation and low‑grade endotoxemia, although IS is more acutely affected by gut barrier disruption and neuroinflammation. In IS, gut dysbiosis also contributes to poststroke complications, such as hemorrhagic transformation, neuropsychiatric issues, and epilepsy. Advances in sequencing and metabolomics enabled identification of microbial signatures associated with the risk for an acute ischemic event and patient prognosis. Therapeutic strategies targeting the gut microbiota-including dietary interventions, probiotics, prebiotics, and synbiotics, fecal microbiota transplantation, and intestinal epithelial stem cell therapy-show promise in mitigating vascular injury and improving recovery. This narrative review highlights current insights into microbiota‑related cardiovascular and cerebrovascular events, with a focus on IS.
心血管疾病和脑血管疾病,包括缺血性心脏病和缺血性中风(IS)等病症,仍然是全球死亡和残疾的主要原因。虽然传统的心血管危险因素(如高血压、糖尿病和动脉粥样硬化)已得到充分证实,但新出现的研究强调了肠道微生物群在心脏和脑血管事件发生和发展中的关键作用。微生物群-肠-脑轴是一个双向通信系统,涉及神经、免疫和代谢途径,将肠道微生物活动与血管和脑功能联系起来。以微生物多样性降低以及有益菌和致病菌分类群之间失衡为特征的生态失调,与全身炎症、内皮功能障碍、肠道通透性增加和血栓形成有关。微生物代谢产物,如氧化三甲胺(TMAO)、短链脂肪酸和胆汁酸衍生物,可调节血脑屏障完整性、血管张力和神经炎症反应。心血管疾病和脑血管疾病都有与微生物群相关的关键机制,包括TMAO介导的血小板活化和低度内毒素血症,尽管IS受肠道屏障破坏和神经炎症的影响更为严重。在IS中,肠道生态失调还会导致中风后并发症,如出血性转化、神经精神问题和癫痫。测序和代谢组学的进展使得能够识别与急性缺血事件风险和患者预后相关的微生物特征。针对肠道微生物群的治疗策略,包括饮食干预、益生菌、益生元、合生元、粪便微生物群移植和肠上皮干细胞治疗,在减轻血管损伤和改善恢复方面显示出前景。这篇叙述性综述重点介绍了目前对与微生物群相关的心血管和脑血管事件的见解,尤其关注IS。